EntryPoint Capital LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

EntryPoint Capital LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,779 shares of the medical device company’s stock, valued at approximately $216,000.

Several other institutional investors also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA raised its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC grew its position in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by insiders.

DexCom Price Performance

DexCom stock opened at $67.74 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $141.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm’s 50-day simple moving average is $82.32 and its 200 day simple moving average is $77.07. The firm has a market capitalization of $26.47 billion, a PE ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the subject of several recent research reports. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.